Navigation Links
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
Date:5/18/2008

- RECORD-1 trial shows RAD001 reduces risk of disease progression by 70% - RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent(R) or Nexavar(R),** with potential to address

unmet medical need - Once-daily oral RAD001 directly targets and continuously inhibits mTOR, a

protein that controls tumor cell division and blood vessel growth - RAD001 is currently being studied in multiple types of cancer including

neuroendocrine, breast, gastric, lung, and lymphoma

EAST HANOVER, N.J., May 19 /PRNewswire/ -- New data show RAD001 (everolimus) may provide an important new treatment option for patients with advanced kidney cancer who have failed standard therapies.

The interim study findings demonstrated that RAD001 significantly extended the time without tumor growth from 1.9 to 4 months and reduced the risk of cancer progression by 70% (hazard ratio = 0.30 with 95% CI 0.22 to 0.40; p- value < 0.0001). The study, RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily), will be presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, US on Saturday, May 31, 2008.

Earlier this year, an independent data monitoring committee stopped the RECORD-1 trial after interim results showed that patients receiving RAD001 experienced a significantly longer time without their cancer worsening compared to patients receiving placebo. The trial included patients whose cancer had stopped responding to approved treatments for renal cell carcinoma (RCC), such as Nexavar(R) (sorafenib) or Sutent(R) (sunitinib), or both.

RAD001 is a once-daily oral therapy that may offer a new approach to cancer treatment by continuously inhibiting the mTOR protein, a central regulator of tumor cell division and blood vessel growth in cancer cells.

"This is the first study to show clinical benefit in patients with
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
3. Ceremeds OSTENE(R) Stops Bone Bleeding Without Added Risk of Surgical Infection, New Study Finds
4. Stem Cell Breakthrough Advances Science Without Ethical Landmines, Says Cardinal
5. Two Major Studies Show: Human Pluripotent Stem Cells without Cloning or Destroying Embryo
6. A Phase II, Randomized, Double Blind, Placebo-Controlled Dose-Escalating Study, Meets the Clinical Endpoints of MTR106 Tablets During the Treatment of Acute Migraine Attacks Without Aura in Females
7. New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects
8. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
9. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
11. Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  Amgen (NASDAQ: AMGN ... partner and managing director of Warburg Pincus LLC, to the ... to welcome Fred Hassan and the deep, global ... Board," said Robert A. Bradway , chairman and chief ... to innovation will serve Amgen well." Mr. Hassan ...
(Date:7/30/2015)...  Cleveland Clinic President Wael Barsoum , M.D. ... that industry is compelled to adopt declining reimbursements throughout ... develop the transformational innovations -- required to thrive in ... by Doug Kohrs , past President and CEO ... that industry must add "episode of care," also known ...
(Date:7/30/2015)... -- Growth of the U.S. nonprescription market is primarily driven ... to the OTC market. Due to an increasingly favorable ... activity over the next five years with several all ... entering the market into existing categories. If ... those with low to moderate likelihood), the market is ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... Aug. 4 Biomoda, Inc. (OTC,Bulletin Board: BMOD) ... submitted to the FDA a pre-IDE (Investigational Device,Exemption) ... assay,for detection of early lung cancer in veterans. ... million over two years towards the,study that will ...
... Rx, a specialty,pharmaceutical company leveraging its proprietary ... products, today announced the,completion of pilot product ... oxalate, a selective serotonin reuptake inhibitor.,Escitalopram oxalate ... and is marketed under the brand name ...
Cached Medicine Technology:FDA Reviewing Biomoda Submission for Cancer Screening Study 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 2MonoSol Rx Completes Thin Film Escitalopram Oxalate Pilot Product Development 3
(Date:7/31/2015)... ... August 01, 2015 , ... The Honor Society of Nursing, ... on the Future of Nursing (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. ... this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit ...
(Date:7/31/2015)... Chicago, IL (PRWEB) , ... July 31, 2015 , ... ... which is currently going on in Chicago at Grant Park. The festival ... every corner of North America to Chicago for the annual Lollapalooza. This unique ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... players to know in predictive health analytics , Jvion continues to disrupt ... firm creates predictive software that targets patient and population level illness to drive ...
(Date:7/31/2015)... Memphis, Tenn. (PRWEB) , ... July 31, 2015 , ... ... at Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to ... partnership focused on cancer research between Methodist Healthcare, The West Clinic and The University ...
(Date:7/31/2015)... , ... July 31, 2015 , ... There’s no better ... even when it comes time to cook the next meal, making July the most ... by practicing best grilling tips and recipes. , Make the next cookout different than ...
Breaking Medicine News(10 mins):Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... LINTHICUM, MD. The AUA is pleased to announce their ... Cancer. Each year, more than 60,000 people are diagnosed ... number of risk factors, including cigarette smoking and exposure ... in 1999 and the report issued today is an ...
... universal hepatitis B immunisation means that most UK citizens ... in this weeks BMJ. , The UK is one ... routinely immunise children against hepatitis B, despite a call ... of vaccine prevention programmes by 1997, writes Andrew Pollard, ...
... binge drinking in the UK rise, doctors in this weeks ... attended hospital with lower abdominal pain. , Although rare, this ... alcohol intake. , Alcohol misuse is costing the NHS up ... by alcohol dependence or poisoning and 22,000 premature deaths each ...
... settlement as ,the ... right thing to do, HOUSTON, Nov. ... agreement with pharmaceutical giant,Merck & Co. Inc. (NYSE: MRK ) that ... over Vioxx, the company,s,controversial pain medication. (Photo: http://www.newscom.com/cgi-bin/prnh/20060623/DAF008 ) ...
... Provides Preliminary Information on Recapitalizations, Asset Sales and ... Anticipated Pre-Tax Charges ... on Accounting Restatement, MCLEAN, Va., Nov. 9 Sunrise Senior Living,Inc. ... the quarter ended September 30, 2007. The Company also,provided preliminary information on ...
... Client Development Officer, SOMERSET, N.J., Nov. 9 ... it has created a new Client Development,and Integration team. ... was recently,promoted to Chief Client Development Officer. The ... across the company,s segments to identify new opportunities to,serve ...
Cached Medicine News:Health News:AUA releases new guidelines on non-muscle invasive bladder cancer 2Health News:Most UK citizens susceptible to hepatitis B infection 2Health News:The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc. 2Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 2Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 3Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 4Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 5Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 6Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 7Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 8Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 9Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 10Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 11Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 12Health News:Sunrise Reports Preliminary Selected Financial and Operating Data for Third-Quarter 2007 13Health News:inVentiv Health Creates Client Development and Integration Team 2Health News:inVentiv Health Creates Client Development and Integration Team 3
A finely parallel striated (scratched) clear plastic membrane encapsulated between glass plates....
BD Visitec IOL Manipulator, blunt tip, formed 10.0mm from end. Fits 0.20mm diameter holes & larger (3/bx, 1 bx/ca). For positioning intraocular lenses. Sure grip handles hand ridge indicating positio...
BD Visitec IOL Manipulator (Lester), 0.25 mm diameter tip angled 45 in, 10 mm from end (3/bx, 1 bx/ca), sterile. For positioning intraocular lenses. Sure grip handles hand ridge indicating position o...
Lewicky lens manipulator. Also available in titanium....
Medicine Products: